NCT03321617View on ClinicalTrials.gov

Glutamate Reducing Interventions in Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 17, 2018

Primary Completion Date

March 13, 2020

Study Completion Date

March 13, 2020

Conditions
Clinical High Risk for Psychosis
Interventions
DRUG

Pomaglumetad methionil

metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

New York State Psychiatric Institute

OTHER

NCT03321617 - Glutamate Reducing Interventions in Schizophrenia | Biotech Hunter | Biotech Hunter